In Vivo High Intrinsic Efficacy of Triazolam: A Positron Emission Tomography Study in Nonhuman Primates
- 1 March 1994
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 62 (3) , 1102-1111
- https://doi.org/10.1046/j.1471-4159.1994.62031102.x
Abstract
The triazolobenzodiazepine triazolam is a central-type benzodiazepine receptor (BZR) ligand that is widely prescribed as a hypnotic agent. Triazolam produces its effects through potentiation of gamma-aminobutyric acid-mediated neurotransmission. Findings reported from in vitro binding studies showed some discrepancies concerning the pharmacological characteristics of triazolam. The present study aims to characterize in vivo the biochemical properties of triazolam, i.e., cerebral pharmacokinetics, interaction with BZR, potency, and intrinsic efficacy. Triazolam was studied in living nonhuman primates using positron emission tomography. Two different studies were carried out: (a) a direct study using [11C]triazolam and (b) an indirect competition study using the radiolabeled BZR antagonist 1C]flumazenil. Results showed that, in the brain in vivo, triazolam binds specifically and competitively to the BZR. Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min). Triazolam is very potent in displacing [11C]flumazenil (ID50 = 28 +/- 6 micrograms/kg). Hill analysis of the displacement curve does not show obvious binding-site heterogeneity. Triazolam is 20 times more potent in displacing [11C]flumazenil and 50 times more potent in inhibiting pentylenetetrazol-induced paroxysmal activity than the full benzodiazepine agonist diazepam. Interestingly, the simultaneous use of positron emission tomography and EEG recording allowed us to show that triazolam-positive intrinsic efficacy is slightly higher (20%) than that of diazepam. An attractive hypothesis proposes that the severity of side effects of BZR ligands is proportional to their intrinsic efficacy. Therefore, our study shows that triazolam side effects, as for other benzodiazepines, may be related to its high intrinsic efficacy in vivo.Keywords
This publication has 40 references indexed in Scilit:
- Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium ApproachesJournal of Cerebral Blood Flow & Metabolism, 1993
- Triazolam is more efficacious than diazepam in a broad spectrum of recombinant GABAA receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Evaluation of a PET scanner in 2D and 3D acquisition modePublished by Institute of Electrical and Electronics Engineers (IEEE) ,1992
- In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primatesBrain Research, 1991
- In vivo benzodiazepine receptor occupancy by CL 218,872 visualized by positron emission tomography in the brain of the living baboon: modulation by GABAergic transmission and relation with anticonvulsant activityExperimental Brain Research, 1991
- Radiosynthesis of a 11C-labelled benzodiazepine receptor agonist: 1-[11C]alprazolamInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1990
- Temperature dependence and GABA modulation of [3H]triazolam binding in the rat brainLife Sciences, 1987
- Triazolam, an Anomalous Benzodiazepine Receptor Ligand: In Vitro Characterization of Alprazolam and Triazolam BindingJournal of Neurochemistry, 1985
- γ-Aminobutyric acid modulation of benzodiazepine receptor binding in vitro does not predict the pharmacologic activity of all benzodiazepine receptor ligandsNeuroscience Letters, 1985
- Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.American Journal of Physiology-Endocrinology and Metabolism, 1978